{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:58:46Z","timestamp":1748926726971},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41390-019-0587-1","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T09:02:54Z","timestamp":1570006974000},"page":"689-696","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia"],"prefix":"10.1038","volume":"87","author":[{"given":"Laurent M. A.","family":"Favi\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cacha M. P. C. D.","family":"Peeters-Scholte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huibert","family":"Tjabbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toine C. G.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"van Bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin M. A.","family":"Rademaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floris","family":"Groenendaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,2]]},"reference":[{"key":"587_CR1","doi-asserted-by":"crossref","unstructured":"Jacobs, S. E. et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst. Rev. CD003311 (2013).","DOI":"10.1002\/14651858.CD003311.pub3"},{"key":"587_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000348823","volume":"104","author":"F Groenendaal","year":"2013","unstructured":"Groenendaal, F. et al. Introduction of hypothermia for neonates with perinatal asphyxia in the Netherlands and flanders and the dutch-flemish working group on neonatal neurology. Neonatology 104, 15\u201321 (2013).","journal-title":"Neonatology"},{"key":"587_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJMoa0900854","volume":"361","author":"DV Azzopardi","year":"2009","unstructured":"Azzopardi, D. V. et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N. Engl. J. Med 361, 1349\u20131358 (2009).","journal-title":"N. Engl. J. Med"},{"key":"587_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.semperi.2015.12.003","volume":"40","author":"F Van Bel","year":"2016","unstructured":"Van Bel, F. & Groenendaal, F. Drugs for neuroprotection after birth asphyxia: Pharmacologic adjuncts to hypothermia. Semin Perinatol. 40, 1\u20138 (2016).","journal-title":"Semin Perinatol."},{"key":"587_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nbd.2015.09.011","volume":"92","author":"H Hagberg","year":"2016","unstructured":"Hagberg, H., David Edwards, A. & Groenendaal, F. Perinatal brain damage: the term infant. Neurobiol. Dis. 92, 102\u2013112 (2016).","journal-title":"Neurobiol. Dis."},{"key":"587_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000106432","volume":"93","author":"F Groenendaal","year":"2007","unstructured":"Groenendaal, F. et al. Nitrotyrosine in human neonatal spinal cord after perinatal asphyxia. Neonatology 93, 1\u20136 (2007).","journal-title":"Neonatology"},{"key":"587_CR7","doi-asserted-by":"publisher","first-page":"F429","DOI":"10.1136\/adc.2005.092114","volume":"91","author":"F Groenendaal","year":"2006","unstructured":"Groenendaal, F., Lammers, H., Smit, D. & Nikkels, P. G. J. Nitrotyrosine in brain tissue of neonates after perinatal asphyxia. Arch. Dis. Child. Fetal Neonatal Ed. 91, F429\u2013F433 (2006).","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"587_CR8","first-page":"105","volume":"26","author":"H Liu","year":"2015","unstructured":"Liu, H. et al. Nitric oxide synthase in hypoxic or ischemic brain injury. Rev. Neurosci. 26, 105\u2013117 (2015).","journal-title":"Rev. Neurosci."},{"key":"587_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neuropharm.2014.03.017","volume":"83","author":"PP Drury","year":"2014","unstructured":"Drury, P. P. et al. NNOS inhibition during profound asphyxia reduces seizure burden and improves survival of striatal phenotypic neurons in preterm fetal sheep. Neuropharmacology 83, 62\u201370 (2014).","journal-title":"Neuropharmacology"},{"key":"587_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2174\/157015910793358150","volume":"8","author":"X Fan","year":"2010","unstructured":"Fan, X., Kavelaars, A., Heijnen, C. J., Groenendaal, F. & van Bel, F. Pharmacological neuroprotection after perinatal hypoxic-ischemic brain injury. Curr. Neuropharmacol. 8, 324\u2013334 (2010).","journal-title":"Curr. Neuropharmacol."},{"key":"587_CR11","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1161\/01.STR.0000028343.25901.09","volume":"33","author":"C Peeters-Scholte","year":"2002","unstructured":"Peeters-Scholte, C. et al. Neuroprotection by selective nitric oxide synthase inhibition at 24\u2009h after perinatal hypoxia-ischemia. Stroke 33, 2304\u20132310 (2002).","journal-title":"Stroke"},{"key":"587_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fneur.2018.00258","volume":"9","author":"LMA Favi\u00e9","year":"2018","unstructured":"Favi\u00e9, L. M. A. et al. Nitric oxide synthase inhibition as a neuroprotective strategy following hypoxic-ischemic encephalopathy: evidence from animal studies. Front. Neurol. 9, 258 (2018).","journal-title":"Front. Neurol."},{"key":"587_CR13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1006\/bbrc.1994.2554","volume":"204","author":"SJ Sup","year":"1994","unstructured":"Sup, S. J., Green, B. G. & Grant, S. K. 2-Iminobiotin is an inhibitor of nitric oxide synthases. Biochem. Biophys. Res. Commun. 204, 962\u2013968 (1994).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"587_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000105479","volume":"29","author":"CH Nijboer","year":"2007","unstructured":"Nijboer, C. H., Kavelaars, A., Van Bel, F., Heijnen, C. J. & Groenendaal, F. Gender-dependent pathways of hypoxia-ischemia-induced cell death and neuroprotection in the immature P3 rat. Dev. Neurosci. 29, 385\u2013392 (2007).","journal-title":"Dev. Neurosci."},{"key":"587_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00221-003-1761-5","volume":"156","author":"C Peeters-Scholte","year":"2004","unstructured":"Peeters-Scholte, C., Van Den Tweel, E., Groenendaal, F. & Van Bel, F. Redox state of near infrared spectroscopy-measured cytochrome aa 3 correlates with delayed cerebral energy failure following perinatal hypoxia-ischaemia in the newborn pig. Exp. Brain Res. 156, 20\u201326 (2004).","journal-title":"Exp. Brain Res."},{"key":"587_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000069044","volume":"24","author":"ERW Van Den Tweel","year":"2002","unstructured":"Van Den Tweel, E. R. W., Peeters-Scholte, C. M. P. C. D., Van Bel, F., Heijnen, C. J. & Groenendaal, F. Inhibition of nNOS and iNOS following hypoxia-ischaemia improves long-term outcome but does not influence the inflammatory response in the neonatal rat brain. Dev. Neurosci. 24, 389\u2013395 (2002).","journal-title":"Dev. Neurosci."},{"key":"587_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/sj.jcbfm.9600007","volume":"25","author":"ERW Van den Tweel","year":"2005","unstructured":"Van den Tweel, E. R. W. et al. Long-term neuroprotection with 2-iminobiotin, an inhibitor of neuronal and inducible nitric oxide synthase, after cerebral hypoxia-ischemia in neonatal rats. J. Cereb. Blood Flow Metab. 25, 67\u201374 (2005).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"587_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1161\/STROKEAHA.112.677922","volume":"44","author":"ST Bjorkman","year":"2013","unstructured":"Bjorkman, S. T. et al. Short-term dose-response characteristics of 2-iminobiotin immediately postinsult in the neonatal piglet after hypoxia-ischemia. Stroke 44, 809\u2013811 (2013).","journal-title":"Stroke"},{"key":"587_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1447-0756.2000.tb01316.x","volume":"26","author":"S Ikeno","year":"2000","unstructured":"Ikeno, S. et al. Immature brain injury via peroxynitrite production induced by inducible nitric oxide synthase after hypoxia-ischemia in rats. J. Obstet. Gynaecol. Res. 26, 227\u2013234 (2000).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"587_CR20","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1523\/JNEUROSCI.17-08-02746.1997","volume":"17","author":"S Nogawa","year":"1997","unstructured":"Nogawa, S., Zhang, F., Ross, M. E. & Iadecola, C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17, 2746\u20132755 (1997).","journal-title":"J. Neurosci."},{"key":"587_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0165-3806(03)00068-3","volume":"142","author":"AP Fern\u00e1ndez","year":"2003","unstructured":"Fern\u00e1ndez, A. P. et al. Postnatal changes in the nitric oxide system of the rat cerebral cortex after hypoxia during delivery. Dev. Brain Res. 142, 177\u2013192 (2003).","journal-title":"Dev. Brain Res."},{"key":"587_CR22","unstructured":"Neurophyxia B. V. Phase 1 clinical study: first-in-man 2-IB dose escalation study. https:\/\/www.neurophyxia.com\/files\/results-phase1-clinical-trial.pdf (2009) [cited 11 Mar 2019]"},{"key":"587_CR23","unstructured":"Neurophyxia B. V. Determination of target dose for Phase II study of 2-Iminobiotin (2-IB) in neonates with perinatal asphyxia https:\/\/www.neurophyxia.com\/files\/2012-01-18-Determination-of-target-dose-for-Phase-II.pdf (2012) [cited 11 Mar 2019]"},{"key":"587_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.neuro.2007.01.014","volume":"28","author":"B Clancy","year":"2007","unstructured":"Clancy, B., Finlay, B. L., Darlington, R. B. & Anand, K. J. S. Extrapolating brain development from experimental species to humans. Neurotoxicology 28, 931\u2013937 (2007).","journal-title":"Neurotoxicology"},{"key":"587_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fneur.2013.00036","volume":"4","author":"R Pressler","year":"2013","unstructured":"Pressler, R. & Auvin, S. Comparison of brain maturation among species: an example in translational research suggesting the possible use of bumetanide in newborn. Front. Neurol. 4, 36 (2013).","journal-title":"Front. Neurol."},{"key":"587_CR26","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford, N., Heo, Y.-A. & Anderson, B. A pharmacokinetic standard for babies and adults. J. Pharm. Sci. 102, 2941\u20132952 (2013).","journal-title":"J. Pharm. Sci."},{"key":"587_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11319360-000000000-00000","volume":"49","author":"MPH Van den Broek","year":"2010","unstructured":"Van den Broek, M. P. H., Groenendaal, F., Egberts, A. C. G. & Rademaker, C. M. A. Effects of hypothermia on pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 49, 277\u2013294 (2010).","journal-title":"Clin. Pharmacokinet."},{"key":"587_CR28","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/cpt.748","volume":"103","author":"Y Bijleveld","year":"2018","unstructured":"Bijleveld, Y. et al. Population pharmacokinetics of amoxicillin in term neonates undergoing moderate hypothermia. Clin. Pharm. Ther. 103, 458\u2013467 (2018).","journal-title":"Clin. Pharm. Ther."},{"key":"587_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1542\/peds.2008-2942","volume":"124","author":"X Liu","year":"2009","unstructured":"Liu, X., Borooah, M., Stone, J., Chakkarapani, E. & Thoresen, M. Serum gentamicin concentrations in encephalopathic infants are not affected by therapeutic hypothermia. Pediatrics 124, 310\u2013315 (2009).","journal-title":"Pediatrics"},{"key":"587_CR30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns, G. L. et al. Developmental pharmacology \u2014 drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157\u20131167 (2003).","journal-title":"N. Engl. J. Med."},{"key":"587_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12098-013-1068-x","volume":"81","author":"J Karlo","year":"2014","unstructured":"Karlo, J., Bhat, B. V., Koner, B. C. & Adhisivam, B. Evaluation of renal function in term babies with perinatal asphyxia. Indian J. Pediatr. 81, 243\u2013247 (2014).","journal-title":"Indian J. Pediatr."},{"key":"587_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/jp.2014.186","volume":"35","author":"H Aly","year":"2015","unstructured":"Aly, H. et al. Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. J. Perinatol. 35, 186\u2013191 (2015).","journal-title":"J. Perinatol."},{"key":"587_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/pr.2015.101","volume":"78","author":"MC Baserga","year":"2015","unstructured":"Baserga, M. C. et al. Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatr. Res. 78, 315\u2013322 (2015).","journal-title":"Pediatr. Res."},{"key":"587_CR34","doi-asserted-by":"publisher","first-page":"e20160191","DOI":"10.1542\/peds.2016-0191","volume":"137","author":"YW Wu","year":"2016","unstructured":"Wu, Y. W. et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics 137, e20160191 (2016).","journal-title":"Pediatrics"},{"key":"587_CR35","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/00004647-199609000-00023","volume":"16","author":"Z Huang","year":"1996","unstructured":"Huang, Z. et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab. 16, 981\u2013987 (1996).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"587_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3171\/jns.2003.98.6.1271","volume":"98","author":"M Karabiyikoglu","year":"2003","unstructured":"Karabiyikoglu, M., Han, H. S., Yenari, M. A. & Steinberg, G. K. Attenuation of nitric oxide synthase isoform expression by mild hypothermia after focal cerebral ischemia: variations depending on timing of cooling. J. Neurosurg. 98, 1271\u20131276 (2003).","journal-title":"J. Neurosurg."},{"key":"587_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2017.00971","volume":"8","author":"K Zitta","year":"2018","unstructured":"Zitta, K. et al. 2-iminobiotin superimposed on hypothermia protects human neuronal cells from hypoxia-induced cell damage: an in vitro study. Front. Pharm. 8, 1\u201311 (2018).","journal-title":"Front. Pharm."},{"key":"587_CR38","doi-asserted-by":"publisher","unstructured":"Diederen, C. M. J., van Bel, F. & Groenendaal, F. Complications during therapeutic hypothermia after perinatal asphyxia: a comparison with trial data. Ther. Hypothermia Temp. Manag. https:\/\/doi.org\/10.1089\/ther.2017.0046 (2018).","DOI":"10.1089\/ther.2017.0046"},{"key":"587_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(15)00347-6","volume":"15","author":"D Azzopardi","year":"2016","unstructured":"Azzopardi, D. et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol. 15, 145\u2013153 (2016).","journal-title":"Lancet Neurol."},{"key":"587_CR40","doi-asserted-by":"publisher","first-page":"e113575","DOI":"10.1371\/journal.pone.0113575","volume":"9","author":"T Alderliesten","year":"2014","unstructured":"Alderliesten, T. et al. Neuroprotection by argon ventilation after perinatal asphyxia: a safety study in newborn piglets. PLoS ONE 9, e113575 (2014).","journal-title":"PLoS ONE"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0587-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-019-0587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:28:10Z","timestamp":1684618090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-019-0587-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1038\/s41390-019-0587-1","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,2]]},"assertion":[{"value":"28 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.P.C.D.P.-S., F.v.B., and F.G. are the inventors of 2-iminobiotin as a neuroprotective agent in neonates with hypoxic\u2013ischemic encephalopathy. C.M.P.C.D.P.-S. and H.T. are shareholders and consultants of Neurophyxia BV. P.V. is employed at LAP&P Consultants BV. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}